Construction and identification of rat vascular endothelial growth factor recombinant adenovirus-mediated gene transfer system
Xiwei Zhang
Abstract
Xiwei Zhang
Abstract
Objective To construct the recombinant adenovirus vector carrying rat vascular endothelial growth factor(VEGF) as preparation for later use for genetic transfection.Methods Rat VEGF was obtained by using RT-PCR amplification and then cloned into the shutter plasmid pDC316.Subsequently,this newly constructed plasmid pDC316-VEGF,after identification by nuclease digestion analysis and sequencing analysis,was transfected into human embryonic kidney cells HEK293 by lipofectamine 2000 mediation,together with adenovirus-packaging plasmid pBHGE3.Based on the homologous recombination of the two plasmids within HEK293 cells,the recombinant adenovirus vector carrying VEGF,VDC316-VEGF,was created.VDC316-VEGF was subsequently identified using PCR,purified using repeated plaque passages,proliferated using freezing and melting within HEK293 cells,and titrated using 50% Tissue Culture Infective Dose(TCID50) assay.Results The newly constructed recombinant adenovirus was confirmed carrying rat VEGF by PCR,and its titration value determined based on TCID50 assay was 3×109pfu/ml.Conclusions The recombinant adenovirus carrying rat VEGF was successfully constructed.The newly constructed adenovirus can produce a sufficiently high titration value within HEK293 cells,providing a reliable tool for genetic transfection in further gene therapy researches.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To construct the recombinant adenovirus vector carrying rat vascular endothelial growth factor(VEGF) as preparation for later use for genetic transfection.Methods Rat VEGF was obtained by using RT-PCR amplification and then cloned into the shutter plasmid pDC316.Subsequently,this newly constructed plasmid pDC316-VEGF,after identification by nuclease digestion analysis and sequencing analysis,was transfected into human embryonic kidney cells HEK293 by lipofectamine 2000 mediation,together with adenovirus-packaging plasmid pBHGE3.Based on the homologous recombination of the two plasmids within HEK293 cells,the recombinant adenovirus vector carrying VEGF,VDC316-VEGF,was created.VDC316-VEGF was subsequently identified using PCR,purified using repeated plaque passages,proliferated using freezing and melting within HEK293 cells,and titrated using 50% Tissue Culture Infective Dose(TCID50) assay.Results The newly constructed recombinant adenovirus was confirmed carrying rat VEGF by PCR,and its titration value determined based on TCID50 assay was 3×109pfu/ml.Conclusions The recombinant adenovirus carrying rat VEGF was successfully constructed.The newly constructed adenovirus can produce a sufficiently high titration value within HEK293 cells,providing a reliable tool for genetic transfection in further gene therapy researches.
Key concepts: Recombinant DNA, Lipofectamine, HEK 293 cells, Transfection, Molecular biology, Viral vector, Plasmid, Vascular endothelial growth factor